1.5 Abstract in Rivista

1.5 Abstract in Rivista: [1820] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 101 a 120 di 1.820

Production of biohydrogen and volatile fatty acids from dephenolized olive mill wastewaters in a sequential two-step anaerobic process

2013-01-01 Monti, Matilde; Bertin, Lorenzo; Scoma, Alberto; Fava, Fabio

NOVEL ABCA1 MUTATIONS IN L PATIENTS WITH SEVERE HDL DEFICIENCY WITH OR WITHOUT CLASSIC MANIFESTATIONS OF TANGIER DISEASE

2011-01-01 Zanoni, P; Fasano, T; Deegan, Pb; Park, A; Feher, Md; Gurakan, F; Favari, E; Bernini, F; Calandra, S

External validation of the novel prognostic Meet-URO score in Metastatic Renal Cell Carcinoma on First Line Immune-combination therapy. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK

2024-01-01 Ghose, Aruni; Signori, Alessio; Brown, Nicholas; Haywood, Sophia; Tapia, Jose; Vijay, Anupama; Cheung, Michael; Mahajan, Ishika; Fiala, Ondrej; Abrol, Ritika; Chauhan, Vishwani; Shwe Yee Soe, Yamin; Zargham, Anum; Ashley, Sophie; Smith, Michelle; Hardy, Orla; Johnston, Emma; Sarwer, Abdullah; Kyaw Tun, Kyaw; Challapalli, Amarnath; Shrestha, Roshani; Ürün, Yüksel; Meegan, James; Rescigno, Pasquale; Parkes, Joanne; Smalley, Benjamin; Anpalakhan, Shobana; Buono, Francesco; Poprach, Alexandr; Yuen Chun Teoh, Jeremy; Murianni, Veronica; Catalano, Fabio; Bimbatti, Davide; Buti, Sebastiano; Fornarini, Giuseppe; Banna, Giuseppe; Elena Rebuzzi, Sara

External validation of the GRade, Age, Nodes and Tumor (GRANT) score for patients with surgically treated papillary renal cell carcinoma. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK.

2024-01-01 Maffezzoli, Michele; Signori, Alessio; Buti, Sebastiano

EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study

2024-01-01 Peroni, M.; Leonetti, A.; Agnetti, V.; Pratticò, F.; Manini, M.; Acunzo, A.; Rapacchi, E.; Mazzaschi, G.; Perrone, F.; Bordi, P.; Trapani, S.; Bacchini, G. P.; Buti, S.; Tiseo, M.

1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis

2024-01-01 Stellato, M.; Giannatempo, P.; Polymeropoulos, A.; Guadalupi, V.; Claps, M.; Ambrosini, P.; Raggi, D.; Rametta, A.; Cavalli, C.; Gusmaroli, E.; Ortega, C.; Tucci, M.; Buti, S.; Pipitone, S.; Iacovelli, R.; Calareso, G.; Alessi, A.; Procopio, G.; Miceli, R.; Necchi, A.

1716P Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)

2024-01-01 Catalano, M.; Roviello, G.; Buti, S.; Massari, F.; Li, H.; Park, S. H.; Grande, E.; Kucharz, J.; Fiala, O.; Poprach, A.; Buchler, T.; Seront, E.; Ansari, J.; Myint, Z. W.; Bhuva, D. M.; Bamias, A.; Ghosn, M.; Andrey, S.; Santoni, M.; Santini, D.

2014P Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)

2024-01-01 Giannatempo, P.; Polymeropoulos, A.; Stellato, M.; Ambrosini, P.; Gusmaroli, E.; Cavalli, C.; Guadalupi, V.; Claps, M.; Raggi, D.; Rametta, A.; Ortega, C.; Tucci, M.; Buti, S.; Pipitone, S.; Iacovelli, R.; Calareso, G.; Alessi, A.; Procopio, G.; Miceli, R.; Necchi, A.

LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial

2024-01-01 Ciccarese, C.; Porcari, S.; Buti, S.; Fornarini, G.; Primi, F.; Giudice, G. C.; Damassi, A.; Giron Berrios, J. R.; Stumbo, L.; Arduini, D.; Severino, A.; Rondinella, D.; Masucci, L.; Sanguinetti, M.; Gasbarrini, A.; Cammarota, G.; Segata, N.; Tortora, G.; Ianiro, G.; Iacovelli, R.